3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
8
Breast Neoplasms
8
Carcinoma, Ovarian Epithelial
4
Carcinoma, Non-Small-Cell Lung
4
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma
2
Uterine Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thrombocytopenia
1
Primary Breast Cancer
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Pathologic Complete Response
1
Paranasal Sinus Neoplasms
1
Ovarian Diseases
1
Neutropenia
1
Neoplasms, Unknown Primary
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Interventions
Fluorouracil
41
Radiotherapy
38
Cisplatin
35
Oxaliplatin
32
Leucovorin
24
Paclitaxel
22
Irinotecan
20
Docetaxel
17
Neoadjuvant Therapy
14
Carboplatin
13
Radiation
12
Capecitabine
12
Surgical Procedures, Operative
10
Cetuximab
8
Biopsy
8
durvalumab
7
Gefitinib
7
Chemotherapy, Adjuvant
7
tremelimumab
6
pembrolizumab
6
Nivolumab
6
Magnetic Resonance Spectroscopy
6
Folfox protocol
6
Taxes
5
Immunohistochemistry
5
Endoscopy
5
Gene Expression Profiling
4
Epirubicin
4
Drug Therapy
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma Of Esophagus
×
CP protocol
×
Clear all
NCT01404156
2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3
Completed
29 enrolled